GLP-1 / Weight Management
Bioglutide
Bioglutide is an investigational oral GLP-1 receptor agonist in clinical development for type 2 diabetes and obesity. It is designed to overcome the bioavailability challenges that typically limit oral peptide therapeutics through proprietary formulation technology. Early-phase clinical data suggest it may provide glycemic control and weight management benefits comparable to injectable GLP-1 agonists.
Quick Facts
Also known asNA-931
CategoryGLP-1 / Weight Management
Half-life20 hours
Routesoral
FDA statusNot approved
StorageRoom temperature (15-25°C). Reconstituted: 90 days.
Dosing Protocols
| Goal | Dose | Frequency | Route | Cycle | Notes |
|---|---|---|---|---|---|
| Starting/Titration | 50 mg | 1x/day | oral | 12 weeks | 50mg once daily oral capsule. 12+ weeks. Can be taken with or without food. |
| Standard Dose | 100 mg | 1x/day | oral | 12 weeks | 100mg once daily oral capsule. 12+ weeks. |
| Maximum Clinical Dose | 150 mg | 1x/day | oral | 12 weeks | 150mg once daily oral capsule. 12+ weeks. Maximum dose in clinical trials. 13.8% body weight reduction in Phase 2. |
Protocols shown are for informational purposes only. Consult a healthcare provider before starting any peptide protocol.
Track Your Bioglutide Protocol
Log doses, manage vial inventory, set injection reminders, and visualize blood concentration levels.
Start Tracking — FreeCommon Questions
What is the typical dose of Bioglutide?
A common dose for Bioglutide is 50 mg 1x/day via oral. 50mg once daily oral capsule. 12+ weeks. Can be taken with or without food.
What is the half-life of Bioglutide?
The half-life of Bioglutide is approximately 20 hours. This determines how long the peptide remains active in your body and influences dosing frequency.
How should I store Bioglutide?
Store Bioglutide at Room temperature (15-25°C). Oral formulation in clinical development. Store in original packaging per manufacturer guidelines. No reconstitution required. Once reconstituted, use within 90 days.
Is Bioglutide FDA approved?
Bioglutide is not FDA approved and is available for research purposes only. It has not been evaluated by the FDA for safety or efficacy in humans.
References
- Phase 2 Clinical Trial - Obesity (2024) - Randomized, double-blind, placebo-controlled (article)
- Phase 1 Trial - Safety and Pharmacokinetics (2024) - First-in-human study (article)
- EASD 2025 Presentation - 14.8% max weight reduction, 83% mild GI adverse events (article)
- Phase 2 Combination Trial with Tirzepatide (article)
- ADA 2025 Presentation - Metabolic Effects (article)